XORTX Therapeutics (XRTX) Retained Earnings (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Retained Earnings came in at -$24.6 million in Q1 2026, down 12.65% YoY from -$28.2 million in Q1 2025, and down 3.39% on a QoQ basis from -$23.8 million in Q4 2025.
XORTX Therapeutics (XRTX) Retained Earnings (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Retained Earnings data on file, last reported at -$24.6 million in Q1 2026.
- Quarterly Retained Earnings fell 12.65% year-over-year to -$24.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.6 million (down 12.65% YoY) and the FY2025 annual result came in at -$23.8 million, down 45189.53% from the prior year.
- Retained Earnings eased to -$24.6 million in Q1 2026, from -$23.8 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$52605.0 in Q4 2024 to a low of -$24.6 million in Q1 2026.
- A 5-year average of -$17.8 million and a median of -$20.6 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings jumped 99.71% — and 2025, when it plunged 45189.53%.
- Tracing XRTX's Retained Earnings over 5 years: stood at -$14.1 million in 2022, then retreated by 26.39% to -$17.9 million in 2023, then jumped by 99.71% to -$52605.0 in 2024, then sank by 45189.53% to -$23.8 million in 2025, then retreated by 3.39% to -$24.6 million in 2026.
- The last three Retained Earnings figures came in at -$24.6 million (Q1 2026), -$23.8 million (Q4 2025), and -$23.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 4.38 Bn |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | -24.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.63 Mn |
| Dec 31, 2025 | -23.82 Mn |
| Sep 30, 2025 | -23.23 Mn |
| Jun 30, 2025 | -22.58 Mn |
| Mar 31, 2025 | -21.87 Mn |
| Dec 31, 2024 | -52,605.00 |
| Sep 30, 2024 | -21.29 Mn |
| Jun 30, 2024 | -20.70 Mn |
| Mar 31, 2024 | -20.87 Mn |
| Dec 31, 2023 | -17.85 Mn |
| Sep 30, 2023 | -20.55 Mn |
| Jun 30, 2023 | -19.22 Mn |
| Mar 31, 2023 | -17.53 Mn |
| Dec 31, 2022 | -14.13 Mn |
| Sep 30, 2022 | -12.47 Mn |
| Jun 30, 2022 | -11.53 Mn |
| Mar 31, 2022 | -10.35 Mn |
| Dec 31, 2021 | -7.69 Mn |
| Sep 30, 2021 | -14.92 Mn |
| Dec 31, 2020 | -6.17 Mn |